FDA approves UroGen’s Zusduri to treat recurrent bladder cancer - PharmaTimes Approximately 59,000 LG-IR-NMIBC patients experience recurrent disease every year in the US

#bladdercancer #FDA #mitomycin #NMIBC #UroGenPharma #Zusduri #mitomycinintravesicalsolution #FDAapproved #LGIRNMIBC #LGIRNMIBCpatients #FoodandDrugAdministration #bladdercancerpatients #recurrentLGIRNMIBC #TURBT #bladdercancertreatment #ENVISIONclinicaltrial
pharmatimes.com/news/fda-app...